PGT-A can improve your success rate per embryo transfer — but major clinical trials show it doesn't necessarily improve your overall chance of taking home a baby from a single retrieval cycle. It's most useful for women over 37, patients with recurrent miscarriage, and situations where you want to minimize the number of transfers. For younger patients with multiple embryos, the math is more complicated.
What Is PGT-A?
PGT-A stands for Preimplantation Genetic Testing for Aneuploidy. It's a screening test performed on embryos created through IVF before they're transferred to the uterus. The goal is straightforward: identify which embryos have the correct number of chromosomes (46) and which don't.
Chromosomal abnormalities — called aneuploidy — are the single biggest reason IVF embryos fail to implant, miscarry, or result in conditions like Down syndrome (trisomy 21). Aneuploidy rates climb sharply with maternal age, from roughly 30% of embryos at age 30 to over 80% by age 42.
The logic behind PGT-A seems iron-clad: test embryos first, transfer only the normal ones, and improve your odds. But as we'll explore, the reality is considerably more nuanced — and the field's leading professional organizations now acknowledge that.
How the Biopsy Works
On day five or six of embryo development — when embryos have reached the blastocyst stage with 100–200 cells — an embryologist removes 5–10 cells from the trophectoderm (the outer layer that becomes the placenta). This biopsy is sent to a genetics laboratory for analysis using next-generation sequencing (NGS), which can evaluate all 23 pairs of chromosomes in roughly 7–14 days.
Because results take time, embryos are frozen (vitrified) after biopsy and transferred in a later frozen embryo transfer (FET) cycle — adding both time and cost to your treatment.
PGT-A vs. PGT-M vs. PGT-SR
These three tests screen for different things:
| Test | What It Screens | Who Needs It | Cost |
|---|---|---|---|
| PGT-A | Chromosome number (aneuploidy) | General screening — optional for any IVF patient | $3,000–$6,000 |
| PGT-M | Specific inherited single-gene disorders (cystic fibrosis, sickle cell, etc.) | Known carrier couples — medically indicated | $7,000–$12,000 |
| PGT-SR | Structural chromosome rearrangements (translocations) | Known translocation carriers — medically indicated | $5,000–$8,000 |
PGT-M and PGT-SR are medically indicated for patients with known genetic risks — their value is well-established. PGT-A is the one generating debate because it's used as a general screening tool offered to most IVF patients, regardless of specific risk factors.
What the Research Actually Shows
Here's where PGT-A gets complicated. The test does exactly what it promises — it identifies which embryos have normal chromosomes. The question is whether that information actually helps you take home a baby.
In September 2024, the American Society for Reproductive Medicine (ASRM) updated its committee opinion with a landmark statement: "The value of PGT-A as a routine screening test for all patients undergoing in vitro fertilization has not been demonstrated."
This was the first time the field's leading US organization explicitly said PGT-A hasn't been proven to help everyone — even as 44% of US IVF cycles (and climbing) were already using it.
The Key Clinical Trials
Two major randomized controlled trials — considered the gold standard of medical evidence — tested whether PGT-A actually improves outcomes:
What they found: In good-prognosis patients with multiple blastocysts available, there was no significant improvement in cumulative live birth rates per retrieval cycle when comparing PGT-A to conventional IVF without testing.
That doesn't mean PGT-A is useless. What it means is this: PGT-A helps you pick the best embryo to transfer first, but if you would have eventually transferred that embryo anyway, the end result is the same — just reached faster with fewer failed transfers along the way.
Per-Transfer vs. Per-Cycle: The Critical Distinction
This is the most important concept for understanding the PGT-A debate:
| Metric | With PGT-A | Without PGT-A | Verdict |
|---|---|---|---|
| Live birth rate per transfer | ~60% | ~35–40% | PGT-A wins |
| Cumulative live birth rate (all available embryos) | ~50–62% | ~45–60% | Similar |
| Miscarriage rate per transfer | ~10% | ~20–25% | PGT-A wins |
| Number of transfers needed | Fewer | More | PGT-A wins |
| Time to pregnancy | Potentially faster* | May take more cycles | PGT-A wins |
*But PGT-A requires a freeze-all cycle, so you lose 4–6 weeks waiting for results and scheduling the FET.
Here's the catch: when PGT-A labels an embryo "abnormal," it's typically discarded or indefinitely frozen. But research now shows that some embryos labeled abnormal — particularly mosaic embryos — can self-correct and produce healthy babies. By removing them from the transfer pool, PGT-A may inadvertently reduce your total chances.
The Mosaic Embryo Debate
This may be the single most consequential issue in the PGT-A discussion. A mosaic embryo contains a mixture of chromosomally normal and abnormal cells — typically 20–80% abnormal cells in the biopsied sample.
For years, mosaic embryos were routinely discarded along with fully abnormal embryos. The thinking was simple: abnormal is abnormal. But that's changed dramatically.
What We Now Know
- Mosaicism is far more common than previously believed. Newer, more sensitive testing techniques suggest that nearly all blastocysts contain some degree of mosaicism — making "fully euploid" embryos potentially rarer than we thought.
- Mosaic embryos can produce healthy babies. Implantation rates for mosaic embryos are lower than euploid embryos (roughly 40–50% vs. 60%) but they are far from zero. Many clinics now report healthy live births from mosaic transfers.
- The biopsy samples the wrong cells. PGT-A biopsies trophectoderm cells (which become the placenta), not the inner cell mass (which becomes the baby). Studies show these two cell populations don't always match. A "mosaic" trophectoderm biopsy can come from an embryo with a completely normal inner cell mass.
- Professional guidelines have shifted. Both ASRM and the Preimplantation Genetic Diagnosis International Society (PGDIS) now recommend that mosaic embryos should not be automatically discarded and may be considered for transfer after appropriate counseling.
A large multisite study examining over 15,000 single-embryo transfers found that mosaic reporting in PGT-A lacked meaningful clinical predictive value — meaning the "mosaic" label wasn't reliably telling clinicians which embryos would succeed or fail.
What PGT-A Actually Costs
PGT-A is one of the most profitable add-ons in the IVF industry. Understanding the full cost — including the hidden expenses — is essential for making an informed decision.
💰 Full PGT-A Cost Breakdown
The headline number clinics quote — "$3,000 to $5,000 for PGT-A" — only covers the biopsy and lab analysis. Because PGT-A requires a freeze-all approach, you'll also need a separate FET cycle that you might not have needed otherwise. This can nearly double the true cost of the add-on.
The Cost-Effectiveness Argument
Proponents argue PGT-A pays for itself by reducing the number of failed transfers you'll need. Each FET costs $3,000–$6,000, so if PGT-A saves you even one failed transfer, the math works out. This is a legitimate argument — especially for older patients with higher aneuploidy rates.
However, a peer-reviewed cost-effectiveness analysis found PGT-A was not cost-effective in donor oocyte cycles, where aneuploidy rates are low. The incremental cost per additional live birth was over $119,000 in that population. For younger patients with good prognoses, similar dynamics apply.
Insurance Coverage
PGT-A is rarely covered by insurance — even when IVF itself is covered by a state mandate. A few mandates may cover it under broad "related laboratory procedures" language (such as California's SB 729), but most patients pay entirely out of pocket. You can use HSA and FSA funds for PGT-A costs.
→ How to maximize HSA and FSA dollars for fertility treatment
→ IVF insurance coverage by state (2026)
Who Benefits Most (and Who Probably Doesn't)
The evidence doesn't support PGT-A for everyone, but it does suggest certain groups are more likely to benefit. Here's a framework based on current research:
Stronger Case for PGT-A
Aneuploidy rates are 50–80% in this group. PGT-A may improve cumulative live birth rates in women aged 38–40, with one systematic review showing 51.3% vs 44.8% (RR 1.14).
Patients with two or more miscarriages show improved implantation rates, clinical pregnancy rates, and lower miscarriage rates with PGT-A compared to conventional IVF.
If you've had three or more failed transfers, identifying chromosomally normal embryos can help determine whether the problem is embryo quality or uterine receptivity.
If minimizing twin pregnancy risk through single embryo transfer is a priority, PGT-A helps select the single best embryo with confidence.
Weaker Case for PGT-A
Aneuploidy rates are lower (~30%), most embryos will be normal, and sequential transfer without testing often yields the same cumulative result.
With only one or two embryos, PGT-A risk is high: if both test abnormal, you have nothing to transfer — even though some "abnormal" embryos can still produce healthy babies.
Young donor eggs have low aneuploidy rates. Cost-effectiveness analyses show PGT-A is not cost-effective in this population.
When $6,000–$12,000 extra could fund another retrieval cycle instead, the math may favor skipping PGT-A and using that money for additional attempts.
Making Your Decision: A Framework
8 Questions to Ask Your Clinic About PGT-A
If you're considering PGT-A, these questions will help you separate genuine clinical value from upselling:
- "Given my age and diagnosis, what does the evidence say about PGT-A improving my cumulative live birth rate?" — If they can't cite specific data for your population, that's telling.
- "What is your clinic's policy on mosaic embryos?" — Clinics that still discard all mosaics are behind the evidence. Look for a nuanced approach with genetic counseling.
- "What is the full cost, including biopsy, lab, freezing, storage, and the FET cycle?" — Get the total, not just the testing fee.
- "Which genetics laboratory do you use, and what is their false positive/negative rate?" — No test is perfect. Reputable labs should be transparent about error rates.
- "How many cells are biopsied, and has research shown this affects embryo development?" — Standard is 5–10 cells. The biopsy itself carries a small risk of damage.
- "If I have only 1–2 embryos, do you still recommend PGT-A?" — The answer should acknowledge the risk of having nothing to transfer.
- "What is your clinic's per-transfer live birth rate for euploid embryos vs. untested embryos?" — Clinic-specific data is more relevant than national averages.
- "Do you offer PGT-A to all patients, or do you recommend it based on individual factors?" — Clinics that blanket-recommend it to everyone may be prioritizing revenue over evidence-based care.
A Note on PGT-P (Polygenic Screening)
You may have seen advertisements for PGT-P — preimplantation genetic testing for polygenic disorders. This newer, more controversial test attempts to predict an embryo's risk for complex conditions like diabetes, heart disease, or schizophrenia using polygenic risk scores.
In December 2025, ASRM's Ethics and Practice Committees published a joint opinion concluding that PGT-P "lacks proven clinical utility and raises significant scientific and ethical concerns." They stated it should not be used for nonmedical trait selection and that the technology is not ready for routine clinical application.
If a clinic offers PGT-P, approach with extreme caution. The science behind polygenic risk prediction in embryos is in its infancy, and the margin of error is enormous.
Preparing Your Body While You Decide
Whether you choose PGT-A or not, egg and sperm quality matter. The 90-day window before your retrieval cycle is when you can have the most impact.
→ More supplement and lifestyle guidance at LifeFertile.com
Frequently Asked Questions
PGT-A typically costs $3,000–$6,000 per IVF cycle in the US for the testing itself. This includes the clinic's embryo biopsy fee (roughly $2,000–$2,500) and the genetics lab analysis fee (another $2,000–$2,500). Some labs charge an additional $350–$500 per embryo tested. Because PGT-A requires a frozen embryo transfer, the true total add-on cost — including freezing, storage, and FET — is typically $6,000–$12,000.
PGT-A improves per-transfer success rates by helping doctors select chromosomally normal embryos — roughly 60% live birth rate per euploid transfer vs 35–40% without testing. However, major randomized controlled trials have found no significant improvement in cumulative live birth rates per retrieval cycle for good-prognosis patients. The benefit is strongest for women over 37 and patients with recurrent miscarriage.
ASRM's 2024 committee opinion states that "the value of PGT-A as a routine screening test for all patients undergoing IVF has not been demonstrated." They don't recommend it for everyone but acknowledge potential benefits for specific groups, including women over 37 and patients with recurrent pregnancy loss. HFEA and ESHRE have similar positions.
A mosaic embryo contains a mix of chromosomally normal and abnormal cells. Research shows mosaicism is far more common than previously thought, and many mosaic embryos can produce healthy pregnancies with implantation rates of 40–50%. ASRM now recommends against automatically discarding mosaic embryos, though they're typically prioritized below fully euploid embryos for transfer.
PGT-A is rarely covered by insurance, even when IVF is covered by state mandate. Some mandates may cover it under "related laboratory procedures" language, but most patients pay out of pocket. HSA and FSA funds can be used for PGT-A biopsy fees, genetics lab fees, genetic counseling, and the associated FET cycle.
PGT-A screens for chromosome number abnormalities (like Down syndrome). PGT-M tests for specific inherited single-gene disorders (cystic fibrosis, Huntington's, sickle cell). PGT-SR detects structural chromosome rearrangements (translocations, inversions). PGT-M and PGT-SR are medically indicated for patients with known genetic risks. PGT-A is the general screening tool — and the one that's debated.
Paying for IVF + PGT-A?
Explore grants, insurance mandates, employer benefits, HSA/FSA strategies, and government drug programs that can reduce your total costs.
IVF Insurance by State →